Sulfur Hormuz crunch forces 60% Roha capacity run

DMCC Speciality Chemicals Limited — Q4 FY26 Earnings Call (held May 19, 2026)

1. Overall Tone of Management: Neutral

Management acknowledges severe, ongoing external disruptions (Middle East/Hormuz sulfur crunch, Europe weakness, boron supply disruptions) but also states current operational stability (“availability is ensured…”, “now we are able to run at capacity”). However, they repeatedly avoid firm forward projections (“too volatile to give a projection”, “not… futuristic projections”), which keeps the tone from being clearly optimistic.

2. Key Themes from Management Commentary

• Sulfur supply shock driving industry-wide price/availability stress
• “~50% of global sulfur trade is through Hormuz” and imports “virtually stopped.”
• Sulfur price “rising dramatically” and availability constraints forced Roha to run at reduced capacity.
• Operational mitigation to avoid shutdown/restart costs
• At Roha: slowed to “about 60% capacity” for ~“15 days” in March to avoid full shutdown.
• Management emphasizes that shutdown/restart is “expensive,” and downstream products can be affected.
• Boron business normalization after prior-year supplier disruption
• FY25-26: first half disrupted by “boron ore… from our main supplier in Turkey,” plants couldn’t operate.
• Second half: “started… at full capacity” and now has “adequate stock.”
• Revenue growth largely price-pass-through, not margin expansion
• Top line rose sharply (Q4: INR 150 cr → INR 177 cr) “most of this is connected to the price increase… able to pass on.”
• “While we didn’t expand our margins… maintain the absolute margin.”
• Working capital strain from higher commodity prices and boron payment terms
• Working capital increased; short-term borrowings expanded.
• They cite working capital intensity still “less than two months… well within industry norms,” but interest cost rose due to higher absolute borrowings.
• Geographic mix shift
• Europe “continues to struggle” and specialty chemical business reduced there, but “improving in other parts of the world.”
• Latin America development continues; also Japan/China/Korea mentioned.

3. Q&A Analysis

Theme A: Roha sulfur disruption—extent and impact

• Core question(s):
• How prolonged was Roha disruption? Any quantification of volume/revenue foregone?
• Management response:
• Roha affected “in the month of March only.”
• Not a shutdown; ran at “perhaps 60% capacity” for “maybe 15 days.”
• Cause: imports not available; Dahej can source domestically.
• Assessment (evasive/strong/partial):
• Provided directional timing and capacity level, but no quantified revenue/volume loss.

Theme B: Boron non-boric products—demand normalization

• Core question(s):
• Impact of “non-boric” softener disruption (ceramics/glass etc.) in Q4; persistence into Q1 FY27?
• Management response:
• Demand hit due to gas/CNG crisis in consuming centers (Morbi/frits): consumers stopped consuming, causing oversupply/glut.
• They can’t quantify, but argue glut is likely one-time because customers liquidated stocks; “demand overall is less” until gas normalizes.
• Assessment:
• Clear mechanism, but no numbers; relies on qualitative normalization logic.

Theme C: Working capital and interest cost—trajectory

• Core question(s):
• Incremental working capital drawn rate; when will working capital intensity ease?
• Management response:
• Interest cost linked to higher absolute borrowings, not high rates.
• Cites interest as “about 9%, 8.75% to 9%.”
• Working capital intensity still “less than two months” overall; boron and sulfur now “adequate stocks” and “much better position,” but absolute stock/debtors rose.
• Assessment:
• Gives a rate, but no explicit timeline for easing.

Theme D: Latin America traction + pricing pass-through mechanics

• Core question(s):
• Update on Latin America replacement progress; any movement to firm orders?
• Can specialty pass through commodity inflation vs commodity business?
• Management response:
• “Yes… replace most of the European business with business in Latin America.”
• Also developing Japan/Korea/China.
• Pricing pass-through has a lag: contracts negotiated earlier; April–June realization reflects January pricing; next quarter “recover.”
• Assessment:
• Strong on qualitative replacement claim; no order book/quantification.
• Pricing explanation is relatively concrete (contract lag).

Theme E: Asset monetization—land dispute

• Core question(s):
• Plan to monetize land near Ambernath (Nalimbi); evaluation/buyer steps; timeline.
• Management response:
• Land is “near Ambernath… Nalimbi,” forest land; Supreme Court verdict in their favor.
• Maharashtra government “has still not transferred the land back… in spite of the court order.”
• “Looking at options,” but monetization timing “out of my control.”
• Assessment:
• Transparent constraint; no timeline.

Theme F: “Speciality chemicals” narrative—credibility and metrics

• Core question(s):
• Why rename if bulk dominates? When will DMCC be a “true speciality” company?
• Can they show evidence: higher gross margin, lower working capital intensity, stability?
• R&D intensity and whether it’s increased.
• Management response:
• Bulk vs specialty mix: earlier “30% commodities and 60% to 70% bulk chemicals”; now still shifting due to Dahej investment and Europe decline.
• They set a target threshold: “increase our speciality chemical portfolio to at least 50%.”
• Refuses segment reporting: “single segment… chemicals… interlinked… sulfur chemicals feeds into speciality.”
• R&D: “Most of our R&D is focused on process development and process improvements… people cost,” with plans to increase “in the coming quarters.”
• Assessment:
• Directly addresses the narrative challenge but does not provide hard KPIs (R&D spend trend, margin/working-capital by specialty).
• “Single segment” rationale may be legitimate, but it also limits investor verification.

Theme G: Sulfur supply—domestic vs imports; utilization outlook

• Core question(s):
• Domestic sulfur share; import options; expected FY27 utilization for specialty.
• Any force majeure/contract ceiling in China; industry normalization timeline.
• Management response:
• “Most of the sulfur… domestic”; imports “at a trickle.”
• Roha better suited for imports if they resume.
• FY27: “too volatile to give a projection,” but “expect it to be better than… FY25-26.”
• Hormuz resolution would still take “a few months” due to “damage and disruption.”
• Not comparable to COVID: “genuine crunch in supply.”
• Assessment:
• Provides operational stance (capacity currently at full) but no quantitative utilization forecast.

Theme H: Product pipeline—commercialization timing

• Core question(s):
• Whether specialty products under R&D will reach commercial stage in FY27/28; which products.
• Management response:
• Expects commercialization: “we do expect that,” but won’t quantify sales/margins.
• Boron specialties: “a couple of specialties… in the boron business.”
• One product started commercial sales: polymer used in “enhanced oil recovery.”
• Assessment:
• Confirms commercialization progress, but no revenue/margin impact.

4. Guidance / Outlook

Explicit guidance (quantitative)

• None provided (no revenue/margin/capex numeric guidance for FY27).

Implicit signals (qualitative)

• Operations
• “Now we are able to run at capacity and there’s no restriction right now.”
• Roha disruption was limited: “maybe 15 days” at ~60% capacity.
• FY27 outlook
• Specialty chemical capacity utilization: “expect it to be better than it was in FY25-26.”
• But management: “too volatile to give a projection.”
• Specialty portfolio target
• “Increase our speciality chemical portfolio to at least 50%” (narrative milestone, not a formal financial guide).
• R&D
• Plans to increase R&D efforts “in the coming quarters,” but framed as process improvement/people-cost.

5. Standout Statements (direct / revealing)

• On sulfur availability and operational response
• “We did have to slow down the plant… to ensure that we don’t run out of sulfur.”
• Roha: “for maybe 15 days, we ran at perhaps 60% capacity.”
• On margin behavior
• “While we didn’t expand our margins, we did manage to pass on all the price increase to our customers.”
• “Mathematically… margin has come down. But in absolute terms… maintain the absolute margin.”
• On working capital
• Working capital intensity: “less than two months overall… well within the industry norms.”
• Interest rate level: “about 9%, 8.75% to 9%… absolute amount has gone up.”
• On specialty narrative credibility
• “The correct time… as we increase our speciality chemical portfolio to at least 50%.”
• Refusal to segment reporting: “We do not wish to report individual segments… interlinked… sulfur chemicals feeds into the speciality chemicals.”
• On supply chain normalization
• Even if Hormuz opens: “supply chain will take a few months to come back to normal.”
• On commercialization
• “We do expect that” FY27/28 products reach commercial stage, but “difficult… to say… how much are you going to sell.”

6. Red Flags / Positive Signals

Red flags
– No quantitative forward guidance despite repeated investor requests (utilization, specialty margin/working-capital proof, FY27 trajectory).
– Limited verifiability: refusal to provide segment-level margin/working-capital evidence; “single segment” stance reduces transparency.
– Hedged language on normalization: “too volatile,” “out of my control,” “don’t know when,” “dynamic situation.”
– No quantified impact for key disruptions (Roha volume/revenue foregone; non-boric revenue/volume; Latin America order conversion).

Positive signals
– Operational stability claim: “availability is ensured” and “now we are able to run at capacity.”
– Mechanistic explanations for demand/price dynamics (contract lag; gas-driven glut; Hormuz crunch vs COVID).
– Clear milestone for specialty portfolio (50% target) and acknowledgement of R&D plans.

7. Historical Comparison & Consistency Analysis (vs prior 3–4 calls)

a. Change in Tone Over Time

• Current call (Q4 FY26): Neutral
• More emphasis on external macro disruption (Hormuz) and “volatility,” with some operational reassurance (“now… run at capacity”).
• Prior call (Q2 FY26, Nov 2025): More cautious/defensive
• Management described Q2 as “difficult… logistical challenges” and Europe consumption decline.
• Shift classification: More Cautious / No Change
• They still avoid projections, but the narrative now centers more on global sulfur logistics rather than boron distributor transition alone.

b. Tracking Past Commitments vs Outcomes

• Past statement (Q2 FY26): Boron disruption expected to recover as logistics normalized; “from the second half of Q3… normal operation” (stated in Q2 call context).
• What was expected: Boron plants to resume normal operation after distributor/logistics setup.
• What happened (current call): Management says boron plants started “at full capacity” in second half and now have “adequate stock.”

• Flag: ✅ Delivered (boron normalization narrative appears consistent).

• Past statement (Q2 FY26): Latin America/other geographies “shaping up well” and start made to replace Europe.

• What was expected: Replacement progress over subsequent quarters.
• What happened (current call): “replace most of the European business with business in Latin America.”

• Flag: ⏳ Partially Delivered (claim is strong, but no quantification or orderbook evidence provided).

• Past statement (Q2 FY26): No large CAPEX; incremental projects; R&D/process development focus.

• What was expected: Continued cautious capital allocation.
• What happened (current call): Still no futuristic projections; no explicit CAPEX expansion; land monetization remains constrained.
• Flag: ✅ Consistent (no contradiction).

c. Narrative Shifts

• From boron logistics disruption → to sulfur/Hormuz crisis as primary driver
• Q2 FY26: boron distributor transition and Europe consumption decline were dominant.
• Q4 FY26: Hormuz-driven sulfur availability/price shock is the central storyline.
• Specialty growth narrative remains, but evidence request is deferred
• Investors asked for segment proof; management continues to avoid segment reporting and provides only a portfolio % milestone.

d. Consistency & Credibility Signals

• Credibility: Medium
• Positives: operational facts are specific (Roha March-only, ~15 days at 60%).
• Negatives: recurring refusal to provide hard, segment-level KPIs and lack of quantified impacts for major questions; frequent “too volatile” deferrals.
• Explanations are coherent, but verification is limited.

e. Evolution of Key Themes

• Demand / pricing
• Improving in some geographies, but overall demand remains hostage to gas availability (boron non-boric) and sulfur availability (bulk chain).
• Margins
• Still framed as absolute margin maintained via pass-through; no structural margin uplift evidence.
• Expansion
• Dahej investment continues to be the anchor for capacity and supply resilience.
• Geographic strategy
• Europe weakness persists; Latin America replacement claim strengthens, but without numbers.

f. Additional Insights (cross-period intelligence)

• Working capital is becoming a recurring structural issue tied to commodity price levels and boron payment terms (Q2 already discussed working capital needs; Q4 reiterates absolute stock/debtor value increases).
• Specialty “proof” remains the missing link: management’s interlinked-segment argument prevents investors from testing whether specialty is truly de-risking working capital and improving stability.